Spiliotis John
European Interbalkan Medical Center, Thessaloniki, Greece.
Ann Transl Med. 2020 Dec;8(24):1708. doi: 10.21037/atm-20-1486.
Ovarian cancer is a major cause of cancer related-death in women around the world. Recent statistics on the worldwide cancer burden by the International Agency for the research on Cancer revealed ovarian cancer being both the eighth most frequent malignancy in the west countries. Peritoneal metastasis from ovarian cancer is a major challenge in the clinical management. Despite the evidence of the benefit of Intraperitoneal Chemotherapy in ovarian cancer with peritoneal deposits it has not been widely adopted, mainly due to logistical difficulties and less to the logoregional morbidity as pain. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients during the end of cytoreductive surgery (CRS) is a more tolerable feasible method with potential advantages as drug distribution, combination with hyperthermia and application before tumor regrowth. The aim of this article is to investigate the potential benefits of HIPEC explains the rationale, data of major clinical trials meta-analyses and recent randomized trial are presented and explains the indications patient selection and the best time to applicate of this aggressive logo regional treatment.
卵巢癌是全球女性癌症相关死亡的主要原因。国际癌症研究机构最近发布的关于全球癌症负担的统计数据显示，卵巢癌是西方国家第八大常见恶性肿瘤。卵巢癌的腹膜转移是临床治疗中的一大挑战。尽管有证据表明腹腔内化疗对伴有腹膜转移的卵巢癌有益，但该方法尚未得到广泛应用，主要原因是后勤困难，而非局部区域发病率如疼痛等问题。在肿瘤细胞减灭术（CRS）末期对患者进行热灌注腹腔内化疗（HIPEC）是一种更可耐受的可行方法，具有药物分布、与热疗联合以及在肿瘤复发前应用等潜在优势。本文旨在探讨HIPEC的潜在益处，阐述其基本原理，呈现主要临床试验、荟萃分析和近期随机试验的数据，并解释该积极的局部区域治疗的适应证、患者选择及最佳应用时机。
